SAN CARLOS, Calif.--(BUSINESS WIRE)--IncellDx, a precision medicine company advancing novel diagnostics and prognostics to better understand and treat infectious disease and cancer, today announced Todd Pollard has joined its executive leadership team as Chief Operating Officer. In this role, Mr. Pollard will provide strategic guidance and operational oversight as the company prepares for expansion into new markets globally including the UK and EU, scales its immunology/long COVID treatment program, and advances biopharmaceutical development.
Mr. Pollard joins IncellDx with more than 20 years of commercial experience in the life sciences and diagnostics spaces. He has built and led commercial teams at companies including Affymetrix, ThermoFischer and ArcherDx. He was also key contributor in the sale of multiple companies including Celsee and ArcherDx, where he held executive level positions.
“IncellDx is fortunate to expand our leadership team with a seasoned life sciences executive like Todd,” commented Bruce Patterson MD, CEO of IncellDx. “His track record leading and growing innovative companies will be instrumental as we continue to expand and scale IncellDx’s unique integrate business model to include precision diagnostics, telemedicine, therapeutics and wearable subscription services within oncology and immunology.”
“IncellDx is pioneering a novel model that integrates diagnostic methods, tools and integrated services,” said Mr. Pollard. “I’m very pleased to join Dr. Patterson and the IncellDx team as we scale globally to deliver on the promise of precision medicine in areas of high medical need.”
About IncellDx
IncellDx is a precision medicine company advancing novel diagnostics and prognostics to better understand and treat infectious disease and cancer. The company’s innovative technology platform enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers. The company launched the Chronic COVID Treatment Center to apply precision medicine approaches to evaluate, characterize and more effectively address chronic COVID.
